Biosciences’ assays for predicting patient response to tamoxifen
-containing chemotherapy in breast cancer
. The companies believe that once validated and approved, these assays can be combined with Veridex’ currently marketed prognostic tools.
Nuvera will receive an up-front fee and earn performance milestones as the products move through commercialization as well as revenue-based milestones. Nuvera will continue to support test validation by using its expertise in diagnostics and bioinformatics and by leveraging its partnership with University of Texas M.D. Anderson Cancer Center and other cancer centers. Veridex will complete clinical studies and market development for the test as well as commercialize the test. Nuvera will also receive royalty payments for product sales generated by Veridex worldwide.
Nuvera, an M.D. Anderson Cancer Center venture, performed initial development of these multigene assays. The assay for predicting response to tamoxifen was developed from genes that are co-expressed with the estrogen receptor gene. The predictor for taxane-containing chemotherapy response is based on prospective neoadjuvant trials at M.D. Anderson with needle biopsies of HER2-normal, stage I-III breast cancer patients who received taxane-chemotherapy.
Veridex’ CellSearch System automates the detection and enumeration of circulating tumor cells and is currently cleared for the prognosis and monitoring of patients with metastatic breast, colorectal, and prostate cancers. The firm’s second product, GeneSearch Breast Lymph Node Assay, detects the spread of breast cancer into the lymph nodes.